• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Osteoactivin/GP-nmb/DC-HlL-CD44 as immune checkpoint targets for cancer therapy

Research Project

Project/Area Number 17K07225
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Tumor therapeutics
Research InstitutionSaitama Medical University

Principal Investigator

Horiuchi Yutaka  埼玉医科大学, 医学部, 講師 (30608906)

Co-Investigator(Kenkyū-buntansha) 村上 孝  埼玉医科大学, 医学部, 教授 (00326852)
高木 徹  埼玉医科大学, 保健医療学部, 助教 (20536891)
松井 政則  埼玉医科大学, 医学部, 准教授 (50199741)
Project Period (FY) 2017-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywordsがん / ゲノム編集 / 腫瘍 / 細菌 / 感染 / 細胞傷害性リンパ球 / ベクター / 腫瘍細胞死 / 貪食 / 腫瘍微小環境 / 腫瘍微小環境形成 / 癌 / 免疫学 / 免疫チェックポイント / 微小環境
Outline of Final Research Achievements

Osteoactivin/GP-nmb/DC-HlL affects the progression of cancer through binding to Syndecan-4 and CD44.
In this study, we determined guide RNA (gRNA) sequences that can knock out CD44 gene using the CRISPR-Cas9 system, and established knockout tumor cell lines. In addition, the CRISPR/Cas9-system targeting CD44 was electroporated in bacteria to utilize in vivo genome editing. The modified bacteria was infected infected into B16F10 cells. The bacteria-possessing B16F10 cells expressed GFP derive from the CRISPR/Cas9-system.

Academic Significance and Societal Importance of the Research Achievements

CRISPR/Cas9によるゲノム編集システムにより、がん病態の進展に関わる遺伝子を破壊することが可能なガイドRNA配列を決定した。このゲノム編集システムを生体内のがん組織内で機能させることができれば、がんの治療法選択肢が増えることにつながる。
上述のゲノム編集システムを生体腫瘍組織内で機能させる方策として、ベクターシステムとして検討した細菌は、腫瘍細胞で外来遺伝子を発現し、さらに腫瘍細胞に特徴的な細胞変性効果を引き起こした。このことは、本細菌を利用したがんのBacterial therapyの可能性を示唆するものである。

Report

(5 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (2 results)

All 2020

All Journal Article (1 results) (of which Peer Reviewed: 1 results,  Open Access: 1 results) Presentation (1 results)

  • [Journal Article] Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma2020

    • Author(s)
      Seiichiro Inoue, Yutaka Horiuchi, Yumiko Setoyama, Yuta Takeuchi, Yoshifumi Beck, Takashi Murakami, Akio Odaka
    • Journal Title

      J Surg Res.

      Volume: 253 Pages: 201-213

    • DOI

      10.1016/j.jss.2020.03.059

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] Intra-tumoral infection of Salmonella typhimurium primes anti-tumor immune responses against murine B16 melanoma.2020

    • Author(s)
      Yutaka Horiuchi, Takashi Murakami
    • Organizer
      第79回日本癌学会学術総会
    • Related Report
      2020 Annual Research Report

URL: 

Published: 2017-04-28   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi